NeuroPace, Inc. NPCE

NeuroPace Inc (NPCE) raises full-year guidance on 21.3% RNS revenue growth, while navigating an unexpected FDA request for additional IGE data.

Moby summary of NeuroPace, Inc.'s Q2 2026 earnings call

MOUNTAIN VIEW, Calif., August 11, 2026--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.

MOUNTAIN VIEW, Calif., July 28, 2026--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today provided an update on the U.S. Food and Drug Administration review of the Company’s Premarket Approval Panel Track Supplement seeking to expand the labeled indication for the RNS® System to include patients with antiseizure medication-resistant idiopathic generalized epilepsy (IGE).

NeuroPace, Inc. (NASDAQ:NPCE) is one of the 10 Best Brain-Computer Interface Stocks to Buy. On May 29, NeuroPace, Inc. (NASDAQ:NPCE) said it received U.S. Food and Drug Administration approval for ECoG Assistant, the first “AI-driven clinician-enabled feature.” It is designed to help epilepsy care using long-term intracranial EEG data. Built on 124,450 epileptologist-labeled records, the […]